Trials / Not Yet Recruiting
Not Yet RecruitingNCT05316480
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
Preliminary Exploration of Therapeutic Efficacy of Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.
Detailed description
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with various types of cancer with EGFR overexpression. The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimotuzumab | nimotuzumab 200mg/week |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2025-04-30
- Completion
- 2026-12-30
- First posted
- 2022-04-07
- Last updated
- 2022-04-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05316480. Inclusion in this directory is not an endorsement.